Terlipressin
Terlipressin reduced need for renal replacement therapy 1 year after liver transplant
CHARLOTTE, N.C. — A subgroup analysis of liver transplant patients with hepatorenal syndrome type 1 demonstrated that terlipressin decreased the need for renal replacement therapy up to 12 months following transplantation.
Terlipressin should be used with caution in hepatorenal syndrome type 1, grade 3 ACLF
Patients with hepatorenal syndrome type 1 and advanced acute-on-chronic liver failure had significantly greater incidence of respiratory failure and 90-day mortality when treated with terlipressin vs. placebo, according to research.
VIDEO: Serum creatinine linked to adverse events in HRS-AKI treated with terlipressin
In this exclusive video, Andrew Allegretti, MD, MSc, discussed a post hoc analysis assessing serum creatinine in patients treated with terlipressin for hepatorenal syndrome-acute kidney injury.
VIDEO: Terlipressin safe, effective for esophageal bleeding, liver cirrhosis
LAS VEGAS — In this video exclusive, Kevin Moore, MD, discussed a study assessing real-world outcomes in patients with esophageal variceal hemorrhage and liver cirrhosis treated with terlipressin.
VIDEO: Early treatment with Terlipressin benefits patients with hepatorenal syndrome
In this exclusive video, Andrew Allegretti, MD, MSc, discusses his poster from The Liver Meeting Digital Experience that explored factors associated with response to terlipressin treatment in patients with hepatorenal syndrome.
FDA: More data needed to approve terlipressin NDA for hepatorenal syndrome type 1
Although the FDA accepted a new drug application for terlipressin to treat hepatorenal syndrome type 1, the agency has issued a complete response letter to Mallinckrodt plc stating that more data are required before the NDA can be approved.
FDA recommends approval of terlipressin for treatment of HRS-1 despite concerns
Study shows terlipressin improves kidney function in hepatorenal syndrome
Newly published research from the United Kingdom demonstrates terlipressin is effective for improving kidney function in hospitalized patients with hepatorenal syndrome type 1.
Terlipressin demonstrates ‘major advance’ in hepatorenal syndrome treatment
BOSTON — In this exclusive video from The Liver Meeting 2019, Arun Sanyal, MD, professor of medicine at Virginia Commonwealth University, discusses results of the CONFIRM trial, which demonstrated that terlipressin was effective in improving renal function and achieving hepatorenal syndrome reversal in a significant percentage of patients with hepatorenal syndrome type 1.